HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Netrin-1 improves post-injury cardiac function in vivo via DCC/NO-dependent preservation of mitochondrial integrity, while attenuating autophagy.

Abstract
Reperfusion injury of the heart is a severe complication of angioplasty treatment of acute myocardial ischemia, for which no therapeutics are currently available. The present study aimed to identify whether and how a novel protein, netrin-1, induces cardioprotection in vivo during ischemia/reperfusion (I/R) injury. Wild type (WT) C57BL6/J mice were subjected to a 30 min coronary occlusion followed by a 24h reperfusion with vehicle (normal saline), netrin-1, UO126 (MEK1/2 inhibitor), PTIO (nitric oxide/NO scavenger), netrin-1/UO126 or netrin-1/PTIO intraventricularly. Some were injected of netrin-1 via tail vein. Netrin-1 at 5μg/kg induced a substantial reduction in infarct size (19.7 ± 5.0% from 41.3 ± 1.8% in the controls), and markedly improved cardiac function as measured by ejection fraction and fractional shortening from echocardiography. Experiments with mice deficient in netrin-1 receptor DCC (deleted in colorectal cancer, DCC+/-), or reperfusion with netrin-1/UO126 or netrin-1/PTIO, attenuated the protective effects of netrin-1, implicating intermediate roles of DCC, ERK1/2 and NO. Netrin-1 induced phosphorylation of ERK1/2 and eNOS was abolished in DCC+/-mice. Electron spin resonance (ESR) determination of NO production from isolated left ventricles demonstrated that netrin-1 improves NO bioavailability, which was attenuated by UO126 or in DCC+/-mice, suggesting upstream roles of DCC and ERK1/2 in NO production. Netrin-1 further reduced mitochondrial swelling and mitochondrial superoxide production, which was absent when co-treated with PTIO or UO126, or in DCC+/-mice, indicating critical roles of DCC, ERK1/2 and NO in preserving mitochondrial integrity. In a permanent coronary ligation model of myocardial infarction (MI) to assess post-MI remodeling, netrin-1 abolished the marked increase in autophagy. In summary, our data demonstrate robust cardioprotective effect of netrin-1 in vivo, as shown by reduced infarct size and improved cardiac function. Mechanistically, this protection is mediated by netrin-1 receptor DCC, and NO dependent preservation of mitochondria. This work clearly establishes a therapeutic potential of netrin-1 for acute treatment of MI, perhaps also for chronic post-MI remodeling. This article is part of a Special Issue entitled: Autophagy and protein quality control in cardiometabolic diseases.
AuthorsJalaleddinne Omar Bouhidel, Ping Wang, Kin Lung Siu, Hong Li, Ji Youn Youn, Hua Cai
JournalBiochimica et biophysica acta (Biochim Biophys Acta) Vol. 1852 Issue 2 Pg. 277-89 (Feb 2015) ISSN: 0006-3002 [Print] Netherlands
PMID24928309 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2014 Elsevier B.V. All rights reserved.
Chemical References
  • Cardiotonic Agents
  • DCC Receptor
  • Dcc protein, mouse
  • Nerve Growth Factors
  • Ntn1 protein, mouse
  • Receptors, Cell Surface
  • Tumor Suppressor Proteins
  • Superoxides
  • Netrin-1
  • Nitric Oxide
  • Nitric Oxide Synthase Type III
  • NADPH Oxidase 4
  • NADPH Oxidases
  • Nox4 protein, mouse
  • Extracellular Signal-Regulated MAP Kinases
Topics
  • Animals
  • Autophagy
  • Cardiotonic Agents (metabolism)
  • DCC Receptor
  • Down-Regulation
  • Enzyme Activation
  • Extracellular Signal-Regulated MAP Kinases (metabolism)
  • Heart Function Tests
  • Male
  • Mice, Inbred C57BL
  • Mitochondria (metabolism)
  • Myocardial Infarction (metabolism, pathology)
  • Myocardial Reperfusion Injury (enzymology, pathology, physiopathology)
  • NADPH Oxidase 4
  • NADPH Oxidases (metabolism)
  • Nerve Growth Factors (metabolism)
  • Netrin-1
  • Nitric Oxide (metabolism)
  • Nitric Oxide Synthase Type III (metabolism)
  • Receptors, Cell Surface (metabolism)
  • Superoxides (metabolism)
  • Tumor Suppressor Proteins (metabolism)
  • Vascular Remodeling

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: